bcr

CNX-774 is a highly specific, irreversible, and orally active BTK inhibitor (IC50<1 nM).

PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.

BCR-ABL-IN-1 is a BCR-ABL tyrosine kinase inhibitor (pIC50: 6.46) and may be used in the research of chronic myelogenous leukemia.

BCR-ABL-IN-2 is a BCR-ABL1 tyrosine kinase inhibitor (IC50s: 57 nM, 773 nM for ABL1 native and ABL1 T315I).

PROTAC BCR-ABL1 ligand 1 is the ligand of PROTAC .

BCR-ABL-IN-10 (compound B4) is a covalent BCR-ABL inhibitor featuring an arylvinylsulfonate (AVS) moiety, demonstrating an IC50 of 43.1 nM against ABL kinase. It forms a covalent and stable adduct with ABL kinase, enabling the sustained inhibition of intrinsic BCR-ABL activity. This compound is utilized in the study of chronic myeloid leukemia (CML).

BCR-ABL-IN-9 (Compound B1) is an inhibitor of BCR-ABL that achieves sustained suppression through the formation of stable covalent bonds with the ABL kinase. It effectively inhibits the activity of ABL kinase (IC50 = 1.2 nM) and possesses anticancer activity.

cSRC BCR-ABL1-IN-1 (compound 16a) is a dual-target inhibitor of the cSRC BCR-ABL1 kinases.

BCR-ABL-IN-11 (Compound 2) is an inhibitor of BCR-ABL, exhibiting anticancer activity against chronic myelogenous leukemia (CML) with an IC50 value of 129.61 μM in K562 cells.

cSRC BCR-ABL-IN-1 (compound 21b) is a potent inhibitor of Bcr-Abl and C-Src, with IC50 values of 56.2 nM and 101 nM, respectively. It exhibits cytotoxicity.

BCR-ABLkinase-IN-3 (dihydrochloride) (example 1) is an effective inhibitor of BCR-ABL, playing a significant role in research on acute myeloid leukemia (AML).

BCR-ABL-IN-3 is a highly effective, irreversible inhibitor of Bcr-Abl, with an IC50 value of ≤100 nM for Ba/F3 Bcr-Abl T3151, displaying significant anti-cancer activity.

BCR-ABL1-IN-1 is a highly potent, orally bioavailable inhibitor with remarkable specificity towards ABL kinase, showing significant promise for elucidating the precise role of ABL kinases in the central nervous system, particularly in preclinical investigations [1].

BCR-ABL-IN-5 is a Bcr-Abl (Breakpoint cluster region-Abelson) kinase inhibitor that acts on Bcr-AblWT (IC50: 0.014 μM) and Bcr-AblT3151 (IC50: 0.45 μM) and exhibits some anti-proliferative effects on leukemic cells. effect.

BCR-ABL-IN-6 (9h) is an imatinib derivative and a selective inhibitor of Bcr-Abl kinase, showing activity on Bcr-AblWT (IC50: 4.6 nM) and Bcr-AblT3151 (IC50: 277 nM). BCR-ABL-IN-6 (9h) is utilized in studying chronic myeloid leukemia treatment.

BCR-ABL-IN-4 is a BCR-ABL inhibitor exhibiting anticancer activity with an inhibitory effect on cancer cell growth, specifically on K562 cells (IC50: 0.67 nM) and BCR-ABL T315I-transfected Ba/F3 cells (IC50: 16 nM).

BCR-ABL-IN-7 is a WT and T315I mutant ABL kinase inhibitor.BCR-ABL-IN-7 potently inhibits WT and T315I mutant ABL kinase activity.BCR-ABL-IN-7 can be used in chronic myelogenous leukemia (CML) research.

GMB-475, also known as PROTAC BCR-ABL1 ligand 1, allosterically targets and binds to the BCR-ABL1 protein. It effectively recruits the E3 ligase Von Hippel-Lindau, leading to the ubiquitination and subsequent degradation of BCR-ABL1 [1].

PROTAC BCR-ABL Degrader-1 (compound PROTAC 1), featuring a 2-oxoethyl linker, induces Bcr-Abl degradation via the ubiquitin-proteasome pathway and exhibits antiproliferative effects on K562 cells, indicating its potential in cancer research [1].

BCR-ABL kinase-IN-3 (example 1), a potent BCR-ABL inhibitor, is significant in the study of acute myeloid leukemia (AML) [1].

BCRP-IN-2 is a compound with BCRP inhibitory activity, exhibiting enhanced inhibition of BCRP upon UV activation. It serves as a valuable probe for studying interactions between quinazoline amine derivatives and BCRP, and it stimulates ATP hydrolysis of the BCRP transporter, leading to increased mitoxantrone accumulation in BCRP-overexpressing H460 MX20 cells.

P-gp/BCRP-IN-1 (compound 19) is a relatively safe, orally active, and efficient inhibitor of the efflux transporters P-gp and BCRP, which reverses resistance and enhances the oral bioavailability of Paclitaxel (PTX) [1].

P-gp/BCRP-IN-2 (compound 15), an oxadiazole derivative, functions as a dual inhibitor targeting both the ABC transporter P-glycoprotein (IC50: 1.6 nM) and BCRP (IC50: 600 nM). Additionally, it bolsters the anti-proliferative impact of Doxorubicin in the drug-resistant HT29/DX and MDCK-MDR1 human adenocarcinoma colon cancer cell lines [1].

33-BCRP inhibitor is a compound that blocks the action of breast cancer resistance protein (BCRP), enhancing the susceptibility of mitoxantrone-resistant H460/MX20 lung cancer cells to the cytotoxic effects of mitoxantrone, both individually and when combined with UV radiation. Additionally, it enhances the sensitivity of KB-C2 epidermal carcinoma cells, which overexpress P-glycoprotein (P-gp) or multidrug resistance protein (MDR), to colchicine-induced apoptosis. Furthermore, at a concentration of 5 µM, it boosts the intracellular accumulation of mitoxantrone in H460/MX20 cells.